Stay updated on SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial
Sign up to get notified when there's something new on the SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial page.

Latest updates to the SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe ClinicalTrials.gov record for the SBRT and nivolumab study is now displayed, with its completed status, study design, eligibility criteria, interventions, outcome measures, and study documents.SummaryDifference57%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide banner announces that NIH agencies are transitioning to use “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer identifies the site as revision v3.7.1 instead of v3.7.0. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedRevision: v3.7.0 was added to the page. A large portion of the Study Documents and related links, including PDFs and protocol documents, were removed, reducing access to supporting materials for the study.SummaryDifference20%

Stay in the know with updates to SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial page.